AGAS

Mitsubishi Shipbuilding Begins Demonstration Testing to Support the Market Launch of the MAmmoSS Ammonia Handling System for Ships

Retrieved on: 
Monday, August 21, 2023
Mitsubishi Heavy Industries, AFSS, Ammonia, Knuth–Bendix completion algorithm, GHG, History, Ship, Innovation Center station, AGAS, MHI, Engineering, Safety, Industrial gas, Shipbuilding

- Testing begun to support the market launch of MAmmoSS, a system package comprising an ammonia fuel supply system and peripheral equipment.

Key Points: 
  • - Testing begun to support the market launch of MAmmoSS, a system package comprising an ammonia fuel supply system and peripheral equipment.
  • TOKYO, Aug 21, 2023 - (JCN Newswire) - Mitsubishi Shipbuilding Co., Ltd., a part of Mitsubishi Heavy Industries (MHI) Group, is currently developing the Mitsubishi Ammonia Supply and Safety System (MAmmoSS), an ammonia handling system to support the utilization of ammonia as marine fuel, which is attracting attention as a means of significantly reducing greenhouse gas (GHG) emissions from ships.
  • As part of this development project, Mitsubishi Shipbuilding has begun demonstration testing of the Ammonia Gas Abatement System (AGAS), a subsystem of MAmmoSS to safely treat surplus ammonia.
  • MammoSS comprises several subsystems in addition to AGAS, including a high-pressure/low-pressure ammonia fuel supply system (AFSS) and an ammonia fuel tank system.

Datopotamab Deruxtecan Combinations Showed Encouraging Tumor Responses in Patients with Advanced Non-Small Cell Lung Cancer in TROPION-Lung02 Phase 1b trial

Retrieved on: 
Monday, June 5, 2023
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Progression-free survival, DCR, AGAS, Journal of Thoracic Oncology, Platinum, Trae Waynes, Outer ring road, ILD, NSCLC, Lung cancer, Immunotherapy, AstraZeneca, PFS, Lung, ALK, Dor, HIV disease progression rates, MD, Patient, Stomatitis, EGFR, DXD, Division, Daiichi Sankyo, Anemia, Internal medicine, Nausea, ADC, Merck, Spacecraft, Merck & Co., Pembrolizumab, PD-L1, ORR, TSE, Fatigue, Disease, Pharmaceutical industry, Medical imaging

In patients receiving triplet datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy, an ORR of 49% was observed (95% CI: 37-61).

Key Points: 
  • In patients receiving triplet datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy, an ORR of 49% was observed (95% CI: 37-61).
  • Disease control rates (DCR) of 84% and 87% were observed in the doublet and triplet cohorts, respectively.
  • Grade 3 or greater treatment-related adverse events (TRAEs) occurred in 31% of patients receiving doublet therapy and 58% of patients receiving triplet therapy.
  • As of the April 7, 2023 data cut-off, 36% and 46% of patients remained on the doublet and triplet therapy, respectively.

Affluent Medical : Affluent Medical announces the launch of a capital increase with preferential subscription rights (PSR)

Retrieved on: 
Monday, August 29, 2022
ISIN, AGAS, TRUST, Article, Medtech, Commercial code, Exercise, Calendar, Urinary incontinence, Equity carve-out, Sale, Person, Maintenance, Board, IPO, Euronext Paris, BSAS, Parity, Map, Intention, Board of directors, Company, Articles of association, Compartment, Second Company Law Directive, Acquisition, Annual, Patient, PSR, Regulatory News Service, Broadcasting, Security (finance), Music, Television, Online gambling, Health insurance, Pharmaceutical industry, Reinsurance, Management, Life insurance, Holding company, News, Mail, Food delivery, Euronext, Director, Association

Prior to the transaction, the share capital of Affluent Medical consists of 18,163,802 fully subscribed and paid-up shares, with a par value of 1 each.

Key Points: 
  • Prior to the transaction, the share capital of Affluent Medical consists of 18,163,802 fully subscribed and paid-up shares, with a par value of 1 each.
  • ISIN code of the share: FR0013333077
    ISIN code of the PSR: FR001400C2C3
    The fund raising proposed by Affluent Medical relates to a capital increase through the issue of New Shares with preferential subscription rights (PSR) maintained.
  • Preferential subscription rights may only be exercised up to a number of PSR allowing the subscription of a whole number of New Shares.
  • The preferential subscription rights not exercised at the end of the subscription period shall automatically lapse.